Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ZOSYN is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in…
Piperacillin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Piperacillin/Tazobactam (Tazocin) | DRUG | - |
Inclusion Criteria: * Hospitalized male and female patients, 18 years of age or older * Patients who have leukemia (acute lymphocytic leukemia \[ALL\], acute myelogenous leukemia \[AML\], chronic lymphocytic leukemia \[CLL\], chronic myelogenous leukemia \[CML\]), that is newly diagnosed, who have ...
Piperacillin is an antibiotic studied in patients with hematologic neoplasms, including hematologic malignancy or lymphoma. It has been evaluated in a Phase 3 trial comparing its safety and efficacy to cefepime in adults 18 years and older. Piperacillin is commonly used as part of the combination product piperacillin/tazobactam.
Piperacillin is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company associated with the clinical development of piperacillin, including the Phase 3 study in patients with hematologic neoplasms.
Piperacillin has been studied in a Phase 3 clinical trial. That trial, NCT00044759, is completed. The study compared the safety and efficacy of piperacillin/tazobactam to cefepime in patients with hematologic malignancy or lymphoma. No active trials of piperacillin are currently listed.
Piperacillin has been evaluated in one completed Phase 3 trial, NCT00044759, titled a study comparing the safety and efficacy of piperacillin/tazobactam to cefepime in patients with hematologic malignancy or lymphoma. The trial enrolled adults 18 years and older in the United States and Canada.